Analysis of Human Immunodeficiency Virus Type 1 Transcriptional Elongation in Resting CD4+ T Cells In Vivo
暂无分享,去创建一个
[1] Robert F. Siliciano,et al. Characterization of Chemokine Receptor Utilization of Viruses in the Latent Reservoir for Human Immunodeficiency Virus Type 1 , 2000, Journal of Virology.
[2] Junmin Peng,et al. Tat Modifies the Activity of CDK9 To Phosphorylate Serine 5 of the RNA Polymerase II Carboxyl-Terminal Domain during Human Immunodeficiency Virus Type 1 Transcription , 2000, Molecular and Cellular Biology.
[3] D. Nickle,et al. Evidence for Human Immunodeficiency Virus Type 1 Replication In Vivo in CD14+ Monocytes and Its Potential Role as a Source of Virus in Patients on Highly Active Antiretroviral Therapy , 2002, Journal of Virology.
[4] D. Richman,et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. , 1999, Science.
[5] M. Clementi,et al. Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo , 1996, Journal of virology.
[6] J. Karn,et al. Activation of Human Immunodeficiency Virus Transcription in T Cells Revisited: NF-κB p65 Stimulates Transcriptional Elongation , 2001, Journal of Virology.
[7] R. Siliciano,et al. Resting CD4+ T Cells from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals Carry Integrated HIV-1 Genomes within Actively Transcribed Host Genes , 2004, Journal of Virology.
[8] G. Pavlakis,et al. Analysis of human immunodeficiency virus type 1 mRNA splicing patterns during disease progression in peripheral blood mononuclear cells from infected individuals. , 1996, AIDS research and human retroviruses.
[9] M. Boyd,et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. , 2001, Blood.
[10] D. Baltimore,et al. The kappaB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth , 1997, Journal of virology.
[11] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[12] D. Hamer,et al. Molecular characterization, reactivation, and depletion of latent HIV. , 2003, Immunity.
[13] K. Jeang,et al. Activation of Integrated Provirus Requires Histone Acetyltransferase , 1998, The Journal of Biological Chemistry.
[14] Y. Korin,et al. Effects of Prostratin on T-Cell Activation and Human Immunodeficiency Virus Latency , 2002, Journal of Virology.
[15] G. Nabel,et al. An inducible transcription factor activates expression of human immunodeficiency virus in T cells , 1987, Nature.
[16] E. Verdin,et al. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro , 2003, The EMBO journal.
[17] R. Siliciano,et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.
[18] A. Rice,et al. Tat-Associated Kinase, TAK, Activity Is Regulated by Distinct Mechanisms in Peripheral Blood Lymphocytes and Promonocytic Cell Lines , 1998, Journal of Virology.
[19] A. Jordan,et al. The site of HIV‐1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation , 2001, The EMBO journal.
[20] A. Rice,et al. Viral transactivators specifically target distinct cellular protein kinases that phosphorylate the RNA polymerase II C-terminal domain. , 1996, Nucleic acids research.
[21] D. Baltimore,et al. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency , 1990, Cell.
[22] D. Margolis,et al. The regulation of HIV-1 gene expression: the emerging role of chromatin. , 2002, DNA and cell biology.
[23] R. Desrosiers,et al. Efficient transcription and replication of simian immunodeficiency virus in the absence of NF-kappaB and Sp1 binding elements , 1996, Journal of virology.
[24] M. Giacca,et al. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[25] B. Peterlin,et al. NF-κB Binds P-TEFb to Stimulate Transcriptional Elongation by RNA Polymerase II , 2001 .
[26] N. Hernandez,et al. RNA-targeted activators, but not DNA-targeted activators, repress the synthesis of short transcripts at the human immunodeficiency virus type 1 long terminal repeat , 1997, Journal of virology.
[27] B. Peterlin,et al. Control of RNA initiation and elongation at the HIV-1 promoter. , 1994, Annual review of biochemistry.
[28] T. Rana,et al. Tat-associated Kinase (P-TEFb): a Component of Transcription Preinitiation and Elongation Complexes* , 1999, The Journal of Biological Chemistry.
[29] A. Burny,et al. HIV‐1 Tat transcriptional activity is regulated by acetylation , 1999, The EMBO journal.
[30] A. Fauci,et al. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[31] Mario Roederer,et al. T-Cell Subsets That Harbor Human Immunodeficiency Virus (HIV) In Vivo: Implications for HIV Pathogenesis , 2004, Journal of Virology.
[32] B. Peterlin,et al. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. , 2001, Molecular cell.
[33] Anthony S. Fauci,et al. Induction of HIV-1 Replication in Latently Infected CD4+ T Cells Using a Combination of Cytokines , 1998, The Journal of experimental medicine.
[34] J. Lisziewicz,et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.
[35] B. Peterlin,et al. Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation. , 1999, Virology.
[36] M. Groudine,et al. Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[37] D. Ho,et al. Use of Real-Time PCR and Molecular Beacons To Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy , 1999, Journal of Virology.
[38] D. Richman,et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[39] E. Fenyö,et al. Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1 , 1990, Journal of virology.
[40] O. Bagasra,et al. Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[41] B. Peterlin,et al. P-TEFb Containing Cyclin K and Cdk9 Can Activate Transcription via RNA* , 2002, The Journal of Biological Chemistry.
[42] R. Gaynor,et al. Absolute dependence on kappa B responsive elements for initiation and Tat‐mediated amplification of HIV transcription in blood CD4 T lymphocytes. , 1995, The EMBO journal.
[43] B. Franza,et al. The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV , 1988, Cell.
[44] Giuseppe Nunnari,et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. , 2002, The Journal of infectious diseases.
[45] R. Siliciano,et al. Analysis of Human Immunodeficiency Virus Type 1 Gene Expression in Latently Infected Resting CD4+ T Lymphocytes In Vivo , 2003, Journal of Virology.
[46] P. Luciw,et al. Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[47] D. Littman,et al. Cytokine Signals Are Sufficient for HIV-1 Infection of Resting Human T Lymphocytes , 1999, The Journal of experimental medicine.
[48] N. Hernandez,et al. Mutations in the carboxy-terminal domain of TBP affect the synthesis of human immunodeficiency virus type 1 full-length and short transcripts similarly , 1996, Journal of virology.
[49] Y. Korin,et al. Interleukin-7 Induces Expression of Latent Human Immunodeficiency Virus Type 1 with Minimal Effects on T-Cell Phenotype , 2002, Journal of Virology.
[50] R. Siliciano,et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.
[51] F. Kashanchi,et al. Chromatin remodeling and modification during HIV-1 Tat-activated transcription. , 2003, Current HIV research.
[52] J. Romeo,et al. Limitation of Tat-associated transcriptional processivity in HIV-infected PBMC. , 1999, Virology.
[53] M Roederer,et al. HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. , 2001, Immunity.
[54] R. Redfield,et al. Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns , 1991, Journal of virology.
[55] Robert F. Siliciano,et al. In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency , 1995, Nature Medicine.
[56] A. Giordano,et al. Transcriptional regulation by targeted recruitment of cyclin-dependent CDK9 kinase in vivo , 1999, Oncogene.
[57] M. Giacca,et al. Regulation of HIV‐1 gene expression by histone acetylation and factor recruitment at the LTR promoter , 2003, The EMBO journal.
[58] D. Margolis,et al. Counterregulation of Chromatin Deacetylation and Histone Deacetylase Occupancy at the Integrated Promoter of Human Immunodeficiency Virus Type 1 (HIV-1) by the HIV-1 Repressor YY1 and HIV-1 Activator Tat , 2002, Molecular and Cellular Biology.
[59] O. Bagasra,et al. HIV-1 latency due to the site of proviral integration. , 1993, Virology.
[60] M. Stevenson,et al. HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection , 2003, Nature.
[61] Martin A. Nowak,et al. Constant Mean Viral Copy Number per Infected Cell in Tissues Regardless of High, Low, or Undetectable Plasma HIV RNA , 1999, The Journal of experimental medicine.
[62] M A Nowak,et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[63] D. Hamer,et al. Rational Design of Drugs That Induce Human Immunodeficiency Virus Replication , 2003, Journal of Virology.
[64] D. Trono,et al. Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency , 1992, Journal of virology.
[65] M. Mathews,et al. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. , 1997, Genes & development.
[66] C. A. Macken,et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.
[67] N. Hernandez,et al. Characterization of the inducer of short transcripts, a human immunodeficiency virus type 1 transcriptional element that activates the synthesis of short RNAs , 1993, Molecular and cellular biology.
[68] A. Rice,et al. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor , 1995, Journal of virology.
[69] D. Richman,et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.
[70] C. Crumpacker,et al. Human immunodeficiency virus type 1 RNA in peripheral blood mononuclear cells of patients receiving prolonged highly active antiretroviral therapy. , 2001, The Journal of infectious diseases.
[71] Yang Shi,et al. The Human Factors YY1 and LSF Repress the Human Immunodeficiency Virus Type 1 Long Terminal Repeat via Recruitment of Histone Deacetylase 1 , 2000, Journal of Virology.
[72] H. Liou,et al. Regulation of the Immune System by NF-κB and IκB , 2002 .
[73] M. Malim,et al. HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: Implications for HIV-1 latency , 1991, Cell.
[74] B. Peterlin,et al. Transcriptional Profiles of Latent Human Immunodeficiency Virus in Infected Individuals: Effects of Tat on the Host and Reservoir , 2003, Journal of Virology.
[75] R. Lempicki,et al. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[76] D. Purcell,et al. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity , 1993, Journal of virology.
[77] P. Luciw,et al. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product , 1987, Nature.
[78] D. Baltimore,et al. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[79] B. Peterlin,et al. Dynamics of Human Immunodeficiency Virus Transcription: P-TEFb Phosphorylates RD and Dissociates Negative Effectors from the Transactivation Response Element , 2004, Molecular and Cellular Biology.
[80] D. Richman,et al. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. , 2001, The Journal of infectious diseases.
[81] E. Verdin,et al. Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity , 1999, Current Biology.
[82] J. Zack,et al. Identification of T cell-signaling pathways that stimulate latent HIV in primary cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[83] C. Caron,et al. Tat-controlled Protein Acetylation* , 2002, The Journal of Biological Chemistry.
[84] T. Rana,et al. HIV-1 Tat Protein Interacts with Mammalian Capping Enzyme and Stimulates Capping of TAR RNA* , 2001, The Journal of Biological Chemistry.
[85] F. Kashanchi,et al. The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[86] T. Rana,et al. Tat stimulates cotranscriptional capping of HIV mRNA. , 2002, Molecular cell.
[87] H. Liou,et al. Regulation of the immune system by NF-kappaB and IkappaB. , 2002, Journal of biochemistry and molecular biology.